XFOR

3.0051.52%
MS

Michael Stephen Wyzga

Independent Non-Executive Chairman of The Board

Mr. Michael Stephen Wyzga, also known as Mike, MBA, serves as Lead Independent Director since August 12, 2025 and was Independent Non-Executive Chairman since May 17, 2022 and served as Independent Non-Executive Director of Mereo BioPharma Group plc since April 23, 2019 until August 12, 2025 and also served as its Independent Deputy Chair of the Board since 2021 until May 17, 2022. He serves as a Director at Glyscend, Inc since March 2023. Mr. Wyzga is Chairman of Mereo BioPharma Group plc of OncoMed Pharmaceuticals, Inc. He served as an Independent Director at Invivyd, Inc. (formerly known as Adagio Therapeutics, Inc.) since July 2021 until May 21, 2024. He served as Interim Chief Financial Officer and Executive Director at Mereo BioPharma Group plc since July 1, 2020 until January 4, 2021. He serves as Director at Tvardi Therapeutics, Inc. since March 2021. He is the Senior Financial Advisor of Yumanity Therapeutics Inc. He served as Interim Chief Financial Officer at Yumanity Therapeutics Inc. since October 2019. He served as the Chief Financial Officer of Aura Biosciences, Inc. He served as an Independent Non-Executive Director of Mereo BioPharma Group plc since April 23, 2019 until August 1, 2020. Mr. Wyzga serves as the President of MSW Consulting Inc. a strategic consulting group focused in the life sciences area. Mr. Wyzga served as an Independent Director of LogicBio Therapeutics, Inc. since September 2018 until November 16, 2022. He serves as an Independent Director at X4 Pharmaceuticals Inc since July 2018 and was its Chairman from July 2018. He is Lead Independent Director of Pharmaceuticals In. from August 2025. He served as an Advisor of Radius Health, Inc. since November 2013. Mr. Wyzga served as an Executive Vice President of Finance at Sanofi Biosurgery (formerly, Genzyme Biosurgery Corporation) since May 2003 until November 2011 and its Chief Accounting Officer since January 1999 and also Chief Financial Officer since July 1999 until November 2011. He served as the Chief Executive Officer and President of Radius Health, Inc. from December 5, 2011 to November 11, 2013. He served as an Executive Vice President of Finance at Genzyme Oncology, Inc. (also known as Genzyme Molecular Oncology, an affiliate of Genzyme Tissue Repair) from May 2003 until November 2011 and its Chief Financial Officer from July 1999 until November 2011 and Chief Accounting Officer since January 1999. He is a biotechnology consultant and has extensive experience in the biotechnology industry. He has spent the majority of his career in leadership roles in the biopharma industry. His experience in the biotech and pharma space. He served as an Executive Vice President of Finance at Genzyme Corporation since May 2003. He served as the Chief Financial Officer of Genzyme Corporation since July 1999 until November 2011. Mr. Wyzga served as the Chief Accounting Officer of Genzyme Corporation until December 2008 and its Principal Accounting Officer since January 1999. He served as Chief Financial Officer, Chief Accounting Officer, Corporate Controller and Senior Vice President - Finance at Genzyme Surgical Products. From January 1999 to July 1999, he served as Senior Vice President, Corporate Controller of Genzyme Corporation and Senior Vice President of Finance from July 1999 to May 2003. He served as the Chief Financial & Accounting Officer and Senior Vice President of Finance at Genzyme General since July 1999. He served as Vice President of Genzyme Biosurgery Corporation since February 1998, Senior Vice President from January 1999 to July 1999 and also Corporate Controller from February 1998 to July 1999. He joined Genzyme Corporation since February 1998. From February 1997 to February 1998, he served as the Chief Financial Officer of Sovereign Hill Software, Inc. From 1991 to 1997, he served various Senior Management Positions with CACHELINK Corporation and Lotus Development Corporation. Prior to his role at Sovereign Hill Software, Mr. Wyzga served as the Chief Financial Officer and Vice President of Finance for CacheLink Corporation and held various management positions at Lotus Development Corporation, including Vice President of Finance and Director of Plans and Controls. He held management positions at Digital Equipment Corp. He had been Chairman of the Board at GenSight Biologics SA since February 2016 until May 29, 2024. He was an Independent Director of Exact Sciences Corporation since February 9, 2015 until June 30, 2021. He serves as Director of X4 Biologics. He served as Dirctor of Akebia Therapeutics, Inc. and Dohman Co. He was a Director of Akebia Therapeutics, Inc. since February 18, 2014 until December 12, 2018. He has been Director of The F. Dohmen Co. since 2010. He served as an Independent Director of OncoMed Pharmaceuticals, Inc. since October 18, 2013. He has been Independent Director of GenSight Biologics SA since July 2015 and serves as its Chairman since March 2, 2016. He has been a Member of Supervisory Board at BioMarin Nederland B.V. since June 17, 2014. He serves as Board Member of Citi Performing Arts and Providence College Business School. Mr. Wyzga serves as a Director of ZappRx, Inc. He served as a Director of Idenix Pharmaceuticals Inc. from March 1, 2012 to August 2014. He previously served as a Director of Prosensa Holding N.V. He served as a Director of Radius Health, Inc. from December 5, 2011 to November 2013. He served as a Member of the Supervisory Board of Prosensa Holding B.V. from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He served as an Independent Director of Altus Pharmaceuticals Inc. since May 2004. He served as a Director of BioMarin Nederland B.V. Mr. Wyzga is an Independent Healthcare Consultant. Mr. Wyzga received an M.B.A. from Providence College and a B.S. in Business Administration from Suffolk University.

Positions